JANX — JANUX THERAPEUTICS INC

Ownership history in Prosight Management, LP  ·  6 quarters on record

This page tracks every 13F SEC filing in which Prosight Management, LP reported a position in JANUX THERAPEUTICS INC (JANX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
6.82% (2025 Q4)
Avg. % of fund
4.98%
First filed
2024 Q3
Last filed
2025 Q4
Quarters held
6
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 2,392,523 +1,527,173 +176.5% 6.82% $33.0M $13.80
2025 Q3 ADDED 865,350 +11,446 +1.3% 4.93% $21.1M $24.44
2025 Q2 ADDED 853,904 +164,003 +23.8% 4.81% $19.7M $23.10
2025 Q1 ADDED 689,901 +360,133 +109.2% 6.12% $18.6M $27.00
2 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    JANX price (monthly, adj. close)

Other funds also holding JANX

As of 2025 Q4 — sorted by position size

RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.58% Lion Point Capital, LP 3Y 7Y 1.36% Logos Global Management LP 3Y 0.83% TCG Crossover Management, LLC 3Y 0.82% ORBIMED ADVISORS LLC 3Y 7Y 0.55% Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. 0.46% SPHERA FUNDS MANAGEMENT LTD. 3Y 7Y 0.42% Cormorant Asset Management, LP 3Y 7Y 0.41% Rangeley Capital, LLC 0.29% Rhenman & Partners Asset Management AB 3Y 7Y 0.29%
← Back to Prosight Management, LP Holdings